Mode
Text Size
Log in / Sign up
N/A N=490

Tuberculosis Research of INA-RESPOND On Drug Resistance

Lung Tuberculosis · MDR TB

Enrolled (actual)
490
Serious AEs
0.0%
Results posted
May 2024
Primary outcome: Primary: Number of MDR TB Cases Amongst New TB Cases and Previously Treated TB Cases — 23; 64 Participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
No Intervention (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Ina-Respond
Primary completion
Nov 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of MDR TB Cases Amongst New TB Cases and Previously Treated TB Cases
23; 64
SECONDARY
Number of Participants Who Were Cured, Failed, Died, Treatment Completion, and Lost to Follow-up
222; 12; 31; 15; 48
SECONDARY
Factors for Treatment Success.
143; 204; 125; 146; 175
SECONDARY
Factors of Treatment Interruption.
56; 81; 51; 54; 75
SECONDARY
TB Case Category
99; 348
SECONDARY
The Performance of AFB and Xpert MTB/RIF
269; 117; 304; 99
SECONDARY
The Performance of Xpert MTB/RIF
6; 2; 165; 2; 25; 112

Summary

This study is a prospective observational cohort study of TB patients who are treated or evaluated at 10 study sites. Patients presenting with cough for 2 weeks or longer with at least one additional TB symptom and a chest X-ray suggestive of TB, will be invited to be enrolled in the study. The signed informed consent will designate their willingness to participate on this study.

Eligibility Criteria

Inclusion Criteria

  • Patients suspected of having pulmonary TB
  • Cough ≥ 2 weeks
  • At least one other TB clinical symptom
  • Fever
  • Unexplained weight loss
  • Loss of appetite
  • Hemoptysis
  • Shortness of breath
  • Chest pain
  • Night sweats
  • Fatigue
  • Suggestive TB on chest x-ray based on pulmonologist or internist consultant of pulmonology opinion
  • Age ≥ 18 years' old
  • Willing to be treated or evaluated at study site
  • Willing to have specimens stored for use in future studies
  • Patient denies having TB treatment for more than 7 days in the last 1 month (30 days).

Exclusion Criteria

Pregnancy or any serious condition includes, but not limited to, liver disease, chronic kidney disease, and psychiatric illness that might interfere with study compliance (based on the clinician judgment).

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02758236). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search